Thrombosis after transjugular intrahepatic portosystemic shunt: an ominous sign?
Editorial

Thrombosis after transjugular intrahepatic portosystemic shunt: an ominous sign?

Yong Lv1, Guohong Han1, Daiming Fan2

1Department of Liver Diseases and Digestive Interventional Radiology, National Clinical Research Center for Digestive Diseases and Xijing Hospital of Digestive Diseases, Fourth Military Medical University, Xi’an 710032, China; 2State Key Laboratory of Cancer Biology, National Clinical Research Center for Digestive Diseases and Xijing Hospital of Digestive Diseases, Fourth Military Medical University, Xi’an 710032, China

Correspondence to: Prof. Guohong Han. Department of Liver Diseases and Digestive Interventional Radiology, Xijing Hospital of Digestive Diseases, Xijing Hospital, Fourth Military Medical University, No. 127 Changle West Road, Xi’an 710032 China. Email: hangh@fmmu.edu.cn.

Provenance: This is a Guest Editorial commissioned by Section Editor Xingshun Qi (Department of Gastroenterology, General Hospital of Shenyang Military Area, Shenyang, China).

Comment on: Yue-Meng W, Li YH, Wu HM, et al. Portal Vein Thrombosis in Patients With Cirrhosis Undergoing Elective Transjugular Intrahepatic Portosystemic Shunt. Clin Appl Thromb Hemost 2017. [Epub ahead of print].


Received: 06 March 2017; Accepted: 09 March 2017; Published: 30 March 2017.

doi: 10.21037/amj.2017.03.07


Transjugular intrahepatic portosystemic shunt (TIPS) is increasingly used for the treatment of complications of portal hypertension, especially variceal bleeding and ascites refractory to conventional therapy (1,2). Development of thrombosis after TIPS placement is an uncommon complication, which was reported to occur in only 3% to 10% of patients when bare stents were used in several large series (3-6). Thrombosis usually develops acutely either at the time the stent is being deployed or within several days of TIPS placement (2,6). The cause of the thrombosis may be leakage of bile into the shunt, hypercoagulable syndromes, stent mispositioning, suboptimal stent sites, or inadequate coverage of the TIPS tract with sufficient stent (2,7-12). The direct result of thrombosis development is occlusion of the TIPS device, blocking flow in the portal vein and directly resulting in the recurrence of the complication of portal hypertension in addition to potentially causing bowel ischemia as a result of venous congestion in cases of thrombosis extending into the splenic and mesenteric veins (7). Thrombosis can be identified by Doppler ultrasound and patency can be re-established by repeat catheterization (2,7). The development of acute thrombosis also can be effectively prevented by prophylaxis anticoagulation or using e-PTFE-coated stents (13,14). One randomized controlled trial (RCT) showed that use of phenprocoumon (an anticoagulant) was associated with a lower rate of complete occlusion within the first three months following TIPS placement (13). In the RCT by Bureau (14), no early thrombosis was observed in the e-PTFE covered stent-graft group (n=39) as compared with three cases in the covered stent-graft group (n=41). A recent RCT also showed that early thromboses were less frequent in patients receiving covered stent TIPS compared with those receiving bare stents (10/67 in bare stent group vs. 3/63 in the covered stent group) (15).

In a recent issue of Clinical and Applied Thrombosis/Hemostasis, Yue-Meng et al. (16) reported their experience on thrombosis in a cohort of cirrhotic patients undergoing elective TIPS. In this study, the prevalence of thrombosis in cirrhotic patients undergoing elective TIPS was 26.7% (27/101), despite using prophylaxis anticoagulation (low-molecular-weight heparin then shifted to aspirin or clopidogrel) and ePTFE-covered stent. This value is unexpectedly higher than that reported in the literatures (3-6). Even though the authors declared this rate was similar to those without TIPS and compared their results with those without TIPS from beginning to end in their paper, it should be noted that development of portal vein thrombosis (PVT) in the presence or absence of TIPS was two distinct situations. In cirrhotic patients without TIPS, a prior decrease in portal blood flow velocity, in combination with a hypercoagulable state caused by cirrhosis and/or concomitant thrombophilic disorders, constitutes the main risk factors (17-19). Thus PVT is not an infrequent occurrence in patients with cirrhosis, with a prevalence ranging from 2% to 23% (20). However, the most determined risk factor has been overcome after TIPS by increasing the blood velocity. Indeed, the reported PVT recurrence rate after TIPS in the study by Luca et al. is only 5% (21). The common causes of thrombosis development after TIPS placement have been discussed above. Therefore, this high prevalence of thrombosis after TIPS in this study, if the report is true, questions the radiologist skills, which is related to stent mispositioning and incorrect release of the stent (7,11,12,14,15,22). Previous studies have shown that deployment of a stent with the cephalic end extending to the hepato-caval junction and the caudal end parallel to the vascular wall of the portal vein is favorable in a TIPS procedure to decrease the risk of thrombosis and shunt dysfunction (10,12). In contrast, an uncovered hepatic vein is more susceptible to shunt thrombosis caused by turbulence and the shear stress of high-velocity blood flow (10-12).

Another interesting finding in this study is that thrombosis after TIPS seem to seldom cause shunt dysfunction as the portion of patients who developed thrombosis (27/101, 27%) was higher than that developed shunt dysfunction (21/101, 21%) and most shunt dysfunction was revealed to be shunt stenosis which seems caused by pseudointimal hyperplasia (16/21, 76%) (16). This low rate shunt dysfunction resulted from thrombosis questions the adverse impact of the thrombosis. In addition, it has been shown that shunting branch of portal vein and stent position is associated with shunt dysfunction, hepatic encephalopathy and survival after TIPS (12). Thus, whether the poorer clinical outcomes in TIPS-treated patients who developed thrombosis are due to their suboptimal stent sites or thrombosis is hard to say.

Furthermore, several aspects in the misuse of statistical methods in this study should be considered. Firstly, the authors compared the results in patients with and without thrombosis; however, other potential confounders were not adjusted. Second, as the development of thrombosis change over time, they should be included in a Cox model treating as time-dependent covariates after adjusting other potential confounders (23).

Collectively, considering the unexpected high incidence of thrombosis after TIPS and inappropriate statistical methods, the results of this study should be interpreted with some caution.


Acknowledgements

None.


Footnote

Conflicts of Interest: The authors have no conflicts of interest to declare.


References

  1. Rössle M. TIPS: 25 years later. J Hepatol 2013;59:1081-93. [Crossref] [PubMed]
  2. Boyer TD, Haskal ZJ, American Association for the Study of Liver Diseases. The Role of Transjugular Intrahepatic Portosystemic Shunt (TIPS) in the Management of Portal Hypertension: update 2009. Hepatology 2010;51:306. [Crossref] [PubMed]
  3. Lind CD, Malisch TW, Chong WK, et al. Incidence of shunt occlusion or stenosis following transjugular intrahepatic portosystemic shunt placement. Gastroenterology 1994;106:1277-83. [Crossref] [PubMed]
  4. LaBerge JM, Somberg KA, Lake JR, et al. Two-year outcome following transjugular intrahepatic portosystemic shunt for variceal bleeding: results in 90 patients. Gastroenterology 1995;108:1143-51. [Crossref] [PubMed]
  5. Rössle M, Siegerstetter V, Huber M, et al. The first decade of the transjugular intrahepatic portosystemic shunt (TIPS): state of the art. Liver 1998;18:73-89. [Crossref] [PubMed]
  6. Tripathi D, Helmy A, Macbeth K, et al. Ten years' follow-up of 472 patients following transjugular intrahepatic portosystemic stent-shunt insertion at a single centre. Eur J Gastroenterol Hepatol 2004;16:9-18. [Crossref] [PubMed]
  7. Cura M, Cura A, Suri R, et al. Causes of TIPS dysfunction. AJR Am J Roentgenol 2008;191:1751-7. [Crossref] [PubMed]
  8. Ducoin H, El-Khoury J, Rousseau H, et al. Histopathologic analysis of transjugular intrahepatic portosystemic shunts. Hepatology 1997;25:1064-9. [Crossref] [PubMed]
  9. Saxon RR, Mendel-Hartvig J, Corless CL, et al. Bile duct injury as a major cause of stenosis and occlusion in transjugular intrahepatic portosystemic shunts: comparative histopathologic analysis in humans and swine. J Vasc Interv Radiol 1996;7:487-97. [Crossref] [PubMed]
  10. Clark TW, Agarwal R, Haskal ZJ, et al. The effect of initial shunt outflow position on patency of transjugular intrahepatic portosystemic shunts. J Vasc Interv Radiol 2004;15:147-52. [Crossref] [PubMed]
  11. Angeloni S, Merli M, Salvatori FM, et al. Polytetrafluoroethylene-covered stent grafts for TIPS procedure: 1-year patency and clinical results. Am J Gastroenterol 2004;99:280-5. [Crossref] [PubMed]
  12. Bai M, He CY, Qi XS, et al. Shunting branch of portal vein and stent position predict survival after transjugular intrahepatic portosystemic shunt. World J Gastroenterol 2014;20:774-85. [Crossref] [PubMed]
  13. Sauer P, Theilmann L, Herrmann S, et al. Phenprocoumon for prevention of shunt occlusion after transjugular intrahepatic portosystemic stent shunt: a randomized trial. Hepatology 1996;24:1433-6. [PubMed]
  14. Bureau C, Garcia-Pagan JC, Otal P, et al. Improved clinical outcome using polytetrafluoroethylene-coated stents for TIPS: results of a randomized study. Gastroenterology 2004;126:469-75. [Crossref] [PubMed]
  15. Perarnau JM, Le Gouge A, Nicolas C, et al. Covered vs. uncovered stents for transjugular intrahepatic portosystemic shunt: a randomized controlled trial. J Hepatol 2014;60:962-8. [Crossref] [PubMed]
  16. Yue-Meng W, Li YH, Wu HM, et al. Portal Vein Thrombosis in Patients With Cirrhosis Undergoing Elective Transjugular Intrahepatic Portosystemic Shunt. Clin Appl Thromb Hemost 2017. [Epub ahead of print]. [Crossref] [PubMed]
  17. Tripodi A, Primignani M, Chantarangkul V, et al. An imbalance of pro- vs anti-coagulation factors in plasma from patients with cirrhosis. Gastroenterology 2009;137:2105-11. [Crossref] [PubMed]
  18. Zocco MA, Di Stasio E, De Cristofaro R, et al. Thrombotic risk factors in patients with liver cirrhosis: correlation with MELD scoring system and portal vein thrombosis development. J Hepatol 2009;51:682-9. [Crossref] [PubMed]
  19. Amitrano L, Brancaccio V, Guardascione MA, et al. Inherited coagulation disorders in cirrhotic patients with portal vein thrombosis. Hepatology 2000;31:345-8. [Crossref] [PubMed]
  20. Qi X, Han G, Fan D. Management of portal vein thrombosis in liver cirrhosis. Nat Rev Gastroenterol Hepatol 2014;11:435-46. [Crossref] [PubMed]
  21. Luca A, Miraglia R, Caruso S, et al. Short- and long-term effects of the transjugular intrahepatic portosystemic shunt on portal vein thrombosis in patients with cirrhosis. Gut 2011;60:846-52. [Crossref] [PubMed]
  22. Shah RP, Sze DY. Complications During Transjugular Intrahepatic Portosystemic Shunt Creation. Tech Vasc Interv Radiol 2016;19:61-73. [Crossref] [PubMed]
  23. Ngwa JS, Cabral HJ, Cheng DM, et al. A comparison of time dependent Cox regression, pooled logistic regression and cross sectional pooling with simulations and an application to the Framingham Heart Study. BMC Med Res Methodol 2016;16:148. [Crossref] [PubMed]
doi: 10.21037/amj.2017.03.07
Cite this article as: Lv Y, Han G, Fan D. Thrombosis after transjugular intrahepatic portosystemic shunt: an ominous sign? AME Med J 2017;2:40.

Refbacks

  • There are currently no refbacks.